Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 30:13:996342.
doi: 10.3389/fneur.2022.996342. eCollection 2022.

Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications

Aurora Zanghì  1 , Carlo Avolio  2   3 , Hans-Peter Hartung  4   5   6 , Emanuele D'Amico  2
Affiliations
Editorial

Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications

Aurora Zanghì et al. Front Neurol. .
No abstract available

Keywords: age; disease modifying therapies; immunosenescence; inflammaging; multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications

References

    1. D'Amico E, Patti F, Zanghì A, Chisari CG, Lo Fermo S, Zappia M. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. Euro J Neurol. (2018) 25:1425–31. 10.1111/ene.13745 - DOI - PubMed
    1. Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, et al. . First-line therapies in late-onset multiple sclerosis: an Italian registry study. Eur J Neurol. (2021) 28:4117–23. 10.1111/ene.15006 - DOI - PMC - PubMed
    1. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci. (2004) 25 (Suppl. 4):S350–5. 10.1007/s10072-004-0339-8 - DOI - PubMed
    1. Zanghì A, D'Amico E, Lo Fermo S, Patti F. Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study. Ther Adv Chronic Dis. (2021) 12:2040622320983121. 10.1177/2040622320983121 - DOI - PMC - PubMed
    1. Ostolaza Ibáñez A, Corroza Laviñeta J, Ayuso Blanco T. Immunosenescence: the role of age in multiple sclerosis. Neurologia. (2020). 10.1016/j.nrl.2020.05.016 - DOI - PubMed

Publication types

LinkOut - more resources